Phreesia, Inc. $PHR Shares Purchased by Meros Investment Management LP

Meros Investment Management LP grew its position in shares of Phreesia, Inc. (NYSE:PHR) by 48.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 478,274 shares of the company’s stock after acquiring an additional 156,137 shares during the quarter. Phreesia comprises 3.2% of Meros Investment Management LP’s portfolio, making the stock its 11th biggest position. Meros Investment Management LP’s holdings in Phreesia were worth $8,092,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PHR. Prosight Management LP acquired a new stake in Phreesia during the fourth quarter worth about $16,533,000. Millennium Management LLC increased its stake in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after acquiring an additional 936,033 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Phreesia during the fourth quarter worth about $15,213,000. Greenhouse Funds LLLP increased its stake in Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after acquiring an additional 557,265 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Phreesia by 807.7% during the fourth quarter. JPMorgan Chase & Co. now owns 507,220 shares of the company’s stock worth $8,582,000 after acquiring an additional 451,339 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Price Performance

Shares of NYSE PHR opened at $9.17 on Tuesday. Phreesia, Inc. has a fifty-two week low of $7.77 and a fifty-two week high of $32.76. The business has a 50 day moving average price of $9.22 and a two-hundred day moving average price of $12.63. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.41. The firm has a market cap of $566.92 million, a PE ratio of 61.15 and a beta of 0.91.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The firm had revenue of $130.94 million during the quarter, compared to analyst estimates of $130.08 million. During the same quarter last year, the firm earned ($0.07) EPS. Phreesia’s quarterly revenue was up 12.9% on a year-over-year basis. Sell-side analysts expect that Phreesia, Inc. will post 0.35 earnings per share for the current fiscal year.

Phreesia News Roundup

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Schall, DJS, and others, reiterated that a securities class action has been filed against Phreesia and reminded investors of the July 13, 2026 lead-plaintiff deadline, keeping legal risk front and center for the stock. Article Title
• Negative Sentiment: The allegations center on claims that Phreesia overstated the durability of pharmaceutical marketing commitments, which could raise concerns about growth visibility and future revenue momentum. Article Title
• Neutral Sentiment: One market commentary piece suggested a downgrade because Phreesia’s growth outlook is worsening, reinforcing a more cautious view on the shares, though this was opinion rather than a company announcement. Article Title

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,176 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $9.06, for a total transaction of $55,954.56. Following the transaction, the general counsel owned 157,309 shares of the company’s stock, valued at $1,425,219.54. This trade represents a 3.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Balaji Gandhi sold 3,829 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total value of $43,114.54. Following the transaction, the chief financial officer directly owned 146,740 shares in the company, valued at approximately $1,652,292.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 50,493 shares of company stock worth $461,983 in the last quarter. Company insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

PHR has been the subject of several research analyst reports. Canaccord Genuity Group dropped their price target on Phreesia from $22.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. DA Davidson reiterated a “buy” rating and issued a $14.00 target price on shares of Phreesia in a research note on Thursday, May 28th. KeyCorp lowered their target price on Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Robert W. Baird reiterated a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research note on Tuesday, March 31st. Finally, Citigroup reiterated a “market perform” rating on shares of Phreesia in a research note on Friday, May 29th. Nine analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $16.65.

Phreesia Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.